

Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)

CRISTINA BICA¹, CAMELIA SANDU¹, ANDRA IULIA SUCEVEANU²,
ELIZA SARBU³, ROXANA ADRIANA STOICA⁴, FLORENTINA GHERGHICEANU⁵,
ROXANA ELENA BOHILTEA⁶, SIMONA DIANA STEFAN^{1,4} and ANCA PANTEA STOIAN⁴

¹National Institute of Diabetes, Nutrition and Metabolic Diseases 'Prof. N.C. Paulescu', 020475 Bucharest;

²Faculty of Medicine, Ovidius University, 900470 Constanta; ³Department of Gastroenterology,

'Carol Davila' University of Medicine and Pharmacy, 050098 Bucharest; ⁴Department of Diabetes, Nutrition and Metabolic Diseases, 'Carol Davila' University of Medicine and Pharmacy, 020475 Bucharest;

⁵Department of Marketing and Medical Technology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest; ⁶Department of Obstetrics and Gynecology, 'Carol Davila'

University of Medicine and Pharmacy, 050098 Bucharest, Romania

Received April 20, 2020; Accepted May 21, 2020

DOI: 10.3892/etm.2020.8882

Abstract. Non-alcoholic fatty liver disease (NAFLD) has a high prevalence in type 2 diabetes mellitus (T2DM) patients, being one of the disorders with a relevant global burden. Cross-sectional studies have shown that patients with T2DM and NAFLD have a higher prevalence of liver fibrosis, compared with the general population. Patients with non-alcoholic steatohepatitis (NASH) and T2DM have an increased mortality and morbidity, therefore they generate substantial health care costs. NASH worsens chronic diabetes complications, and T2DM aggravate the NASH progression to fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). The objectives in NAFLD and NASH therapy are to reduce disease activity, to slow down progression of fibrosis, and to lower the risk factors. Unfortunately, there are no specific validated pharmacological therapies. Several trials have demonstrated that anti-diabetic agents such as thiazolidinones, sodium-glucose co-transporter inhibitors, glucagon like peptide-1 receptor analogs, or dipeptidyl peptidase-4 inhibitors might have complimentary benefits for patients with NAFLD. Some of the effect on reducing steatosis and fibrosis is explained by the weight loss these treatments produce. A goal in standard care is developing screening tools, early and non-invasive diagnosis methods, studying the pleiotropic effects of drugs, together with newer therapeutic agents, which

can target mutual pathogenic mechanisms for diabetes and liver disease.

Contents

1. Introduction
2. NAFLD and insulin resistance - lipotoxicity and glucotoxicity
3. NAFLD evaluation and progression
4. Therapeutic management
5. Anti-diabetic agents targeting NAFLD
6. Conclusions

1. Introduction

The annual prevalence of type 2 diabetes mellitus (T2DM) in 2019 was 463 million adults globally, and is estimated to increase to over 700 million by 2045. Half of the people diagnosed with diabetes are unaware of the disease, making this condition a significant subject of interest for physicians (1). In time, diabetes affects the vessels of major organs such as the heart, kidneys, bladder, eyes, nerves and the liver (2-4). A poor glycemic control in T2DM patients is associated with a higher risk for non-alcoholic fatty liver disease (NAFLD), and the magnified insulin resistance (IR) in NAFLD, usually in the presence of metabolic syndrome (MetS), increases diabetes and cardiovascular risk (2,4).

Obesity is a multifactorial disease with a significant health burden that influences the epidemiology of T2DM and NAFLD (5). Its prevalence has tripled in the last 40-50 years, reaching a pandemic level with over 650 million people worldwide in 2016, and still with an ascending trend (6).

NAFLD is the most frequent hepatic disease, with a prevalence of 47.5% (11.7 millions) in people with T2DM, as showed in

Correspondence to: Dr Roxana Adriana Stoica, Department of Diabetes, Nutrition and Metabolic Diseases, 'Carol Davila' University of Medicine and Pharmacy, 5-7 Ion Movila Street, 020475 Bucharest, Romania

E-mail: roxana88stoica@gmail.com

Key words: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes mellitus, therapeutic agents, nutrition

a large American cohort in 2017 (7). NAFLD affects 17-46% of adults in Western countries, with its prevalence vary depending on age, sex, diagnostic method or ethnicity (8). NAFLD incidence depends on the diagnostic process which has been used, from 20-86 per 1,000 people-years based on liver enzymes and ultrasound (US) to 34 per 1,000 people-years based on proton magnetic resonance spectroscopy ($^1\text{H-MRS}$) (9).

Observational studies published in 2018 estimated a non-alcoholic steatohepatitis (NASH) prevalence of 1.5-6.45% worldwide, with a much higher value of up to 12% in the USA (10). NASH prevalence is expected to increase by more than half by 2030, with the possibility to become the first cause of liver transplant in the USA (10).

NAFLD is defined by excessive hepatic fat accumulation (presence of steatosis) in $>5\%$ of hepatocytes according to histological examination or $>5.6\%$ of hepatocytes assessed by magnetic resonance imaging (MRI). NAFLD consists of two distinct conditions: NAFL and NASH with a different prognosis, which can lead to fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (11). The diagnosis of NAFLD can be made after excluding a daily alcohol consumption of >30 g for men (>21 drinks/week) or >20 g for women (>14 drinks/week), and other possible etiologies for hepatic steatosis (12).

HCC is the fifth most common cancer in men and the seventh most common in women. After lung cancer, it is the second cause of cancer mortality, being responsible for 11% of cancer-related deaths (13).

The reciprocal relationship between T2DM and NAFLD is probably one of the biggest challenges for physicians who treat these patients (12). In the development of NAFLD, several pathophysiological processes are involved, such as alteration in glucose and lipids metabolism, insulin resistance (IR), all common in T2DM. Also, patients with T2DM and NAFLD associate with the same comorbidities, including metabolic syndrome (MetS), hypertension, hypertriglyceridemia, low high-density-lipoprotein-cholesterol and abdominal fat accumulation (14).

NAFLD is strongly associated with obesity, with a prevalence of 80% in obese individuals, compared with 16% of the population with a body mass index (BMI) <25 kg/m 2 , and without metabolic risk factors. Hepatic steatosis is more closely correlated with visceral adiposity (measured as abdominal circumference), than it is associated with BMI because visceral adipose tissue (VAT) is more metabolically active (15,16).

2. NAFLD and insulin resistance - lipotoxicity and glucotoxicity

In NAFLD, insulin resistance (IR), a well-known state of T2DM, affects the muscle, the liver and the adipose tissue (13). Glucotoxicity and lipotoxicity are in strong association, and they contribute together to exacerbate IR and alteration of insulin secretion (14).

Increased adiposity, especially VAT, is often present in NAFLD and T2DM, and is associated with adipocyte insulin resistance and dysfunction (14). This leads to excess free fatty acids (FFA) released into the circulation, and in the end, to an excess fat uptake by the liver, pancreas and skeletal muscles, becoming a vicious cycle. FFAs can be oxidized through mitochondrial β -oxidation or esterified to triglycerides.

Lipotoxicity is strongly correlated to peripheral IR, hepatic gluconeogenesis and glycogenolysis, which lead to hyperglycemia, pancreatic beta-cell dysfunction and alterations in insulin secretion (13).

The hepatocytes and adipocytes from VAT are in close juxtaposition with immune cells, hepatic stellate cells, Kupffer cells, endothelial cells and macrophages where biochemical signalling pathways take place, activated by obesity and a high-fat diet (HFD). This pathway underlies the low-grade chronic inflammation present in hepatic steatosis, also sustained by a high level of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 β) found in mice with high-fat diet (15).

VAT secrete considerable amounts of adipocyte-derived cytokines called adipokines, of which the most well-described are adiponectin and leptin. Leptin controls energy intake and energy spending, metabolism, reproduction and stops lipid accumulation in non-adipose tissues, such as the liver. Obesity is a state of leptin resistance, both central and peripheral, associated with low levels of adiponectin, a cytokine responsible for the modulation of the inflammatory response, intensification of liver fat oxidation and decrease in the activity of fatty acid synthase (14).

Glucotoxicity, a chronic condition in T2DM, causes glucose-induced insulin resistance, cellular dysfunction and a series of metabolic alterations. Individually, fructose and sucrose are considered lipotoxic to hepatocyte activity, because they have been proven to enhance *de novo* lipogenesis and ectopic fat accumulation. Persistent high levels of glycaemia cause both functional and structural harm to beta cells, which develop oxidative stress, increase the production of reactive oxygen species, DNA alteration and pro-apoptotic pathways (13).

Research has been conducted on intestinal microbiota, which determines nutrient consumption, caloric intake, influencing weight and insulin sensitivity (16). The favourable effects of antibiotics on bowel decontamination in patients with cirrhosis that permit bacterial translocation and inactivation are well-known. Still, the effect of microbiota on the progression of liver fibrosis needs to be further studied (16).

3. NAFLD evaluation and progression

Usually, NAFLD is a slowly progressive condition, with fibrosis advancing in a fifth of individuals (11). Comparing to chronic liver diseases, such as hepatitis B or hepatitis C, the natural history of NASH is much more unpredictable (16). The progression of fibrosis in NAFLD depends on genetic factors, extrinsic environmental and intrinsic microbial factors (17). The natural history of NAFLD can be modified, even reverted, through diet and lifestyle changes (18). While some studies support age and diabetes as significant drivers in fibrosis evolution (19), others consider hypertension and AST/ALT ratio more relevant in the prognosis of liver fibrosis (17). Among patients who develop progressive hepatic fibrosis, there are two categories of individuals: rapid progressors (advance from stage 0 to bridging fibrosis or cirrhosis), who are 20% of patients, and slow progressors (progression from stage 0 to stage 1 or 2 of fibrosis) (17). Liver-related morbidity and

mortality increase remarkably with stage 2 of fibrosis and in particular with cirrhosis (16). A study by Ciupińska-Kajor *et al* showed that severe fibrosis and cirrhosis are more frequent in morbidly obese patients (20).

Patients with T2DM have more than a 2-fold increase in the prevalence of NAFLD/NASH, regardless of the diagnostic method, with an ~70% prevalence when sensitive methods are used (21). The prevalence of NAFLD depends on the diagnostic tool used and on different cut-off points selected as usual (e.g., alanine aminotransferase). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are considered poor markers for NAFLD. Liver ultrasound is available, has a low cost, making it suitable for screening routine (22). Hernaez *et al* (23) reported a meta-analysis of the studies which evaluate the accuracy of liver ultrasound in detecting steatosis. This method has 84.8% sensibility (95% confidence interval between 79.5 and 88.9), and 93.6% specificity (95% CI between 87.2 and 97.0) for moderate-severe NAFLD. However, liver ultrasound does not discriminate mild steatosis. Fatty liver index (FLI), a non-invasive algorithm using anthropometric and biological parameters (BMI, waist circumference, plasma triglycerides level, γ -glutamyl transferase), are accepted and validated, in comparison with liver ultrasound, but fibrosis may alter the result. Novel techniques, i.e. controlled attenuation parameter (CAP), ¹H-MRS and MRI-proton density fat fraction are more accurate and are quantifiable, which can be helpful in the follow-up. Techniques that measure hepatic triglyceride accumulation are becoming more widely available. They may become the gold standard for steatosis screening in high-risk patients (22).

Evaluating inflammation and fibrosis are the next important steps after diagnosing NAFLD. Although the gold standard is liver biopsy, some non-invasive scores i.e. FibroTest, NAFLD fibrosis score, BARD score, FIB-4, NAFIC score based on clinical parameters (plasmatic levels for ALT, AST, albumin, BMI, diagnosed diabetes) are also used (24). There are new promising biomarkers (i.e., metabolomics), and genetic tests studied for future implementation. The polymorphism patatin-like phospholipase 3 (PNPLA3; rs 738409) has been associated with more significant accumulation of liver lipids (25). Vibration-controlled transient elastography (FibroScan) and magnetic resonance elastography (MRE) determine the stage of fibrosis, replacing biopsies in some cases. Although MRE is more expensive and not always available, its result does not interfere with BMI, considering patients with T2DM have quite often a higher BMI than the general population (1).

4. Therapeutic management

The aims in NAFLD and NASH therapy are to reduce disease activity, to slow down progression of the fibrosis, and to lower the risk factors. Unfortunately, there are no specific pharmacological therapies validated; consequently, the lifestyle interventions are considered standard of care (13,20). The management of NASH should also include pharmacological treatment of comorbidities such as therapy for hyperglycemia, or dyslipidemia and control of other cardiovascular risk factors (24).

Studies showed an improvement in NAFLD and NASH correlated with the percentage of weight loss following

dedicated programs, such as a hypocaloric diet and 200 min exercises per week (26,27), or after metabolic surgery (28). Some studies found that >7% of weight loss is associated with a decrease in steatosis (26). A more significant weight loss (8-10%) can reverse steatohepatitis, and if >10% is achieved it can lead to considerable regression of fibrosis (29). Patients who undertook bariatric surgery had even more surprising results, so the decrease in steatosis was observed in 90% of patients, decrease in steatohepatitis in ~80% of them, and a reduction in fibrosis was observed in 65% of patients (28).

In a ten-week randomized-controlled trial, patients were given either an omega-3 polyunsaturated fatty acid (PUFA) rich diet or a saturated fat diet. Patients included in the first group had a significantly reduced steatosis assessed with ¹H-MRS (-26% after intervention), in comparison with patients from the saturated fat diet, in whom steatosis had even progressed (+8% after intervention) (29). A series of studies are needed to assess the role of lifestyle intervention as a therapy for patients with NASH (24). The Mediterranean Diet and the Dietary Approach to Stop Hypertension (DASH) are considered effective (30).

The recommendation of caloric intake is 30-35 kcal/kg/day, with adjustment depending on the level of physical activity the patient would reach. Regarding the macronutrients, carbohydrates should make up 45-55% of the daily caloric intake, obtained from whole grains, fruits and vegetables; 20-30% of caloric intake should come from 'healthy' fats, monounsaturated fatty acids (MUFA) and PUFA, found in seeds, nuts, olive oil and fatty fish 'as little thermally processed as possible'. Proteins represent 10-15 to 20% of the total daily caloric requirements, obtained from both animal and vegetable sources. The diet is more beneficial if it includes fiber, antioxidants, probiotics and prebiotics along with 33 ml/kg/day liquids and a moderate sodium restriction (31,32).

5. Anti-diabetic agents targeting NAFLD

Some studies showed an efficacy in reducing steatosis for pioglitazone, liraglutide, vitamin E, obeticholic acid, but cross-comparisons between studies cannot be considered, because of the heterogeneity regarding materials and methods (24). Thiazolidinediones (TZDs), especially pioglitazone, through activating the peroxisome activator-proliferator receptor- γ (PPAR- γ), improve steatosis and fibrosis scores, along with insulin sensitivity in adipose tissue, muscle and liver (33). The study of Cusi *et al* (34) suggests that the administration of pioglitazone in patients with T2DM and NAFLD/NASH leads to improvement in liver fibrosis. The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) showed no benefit regarding the administration of pioglitazone vs. placebo for the primary composite outcome (improvement of the histological lesions), but hepatic steatosis and lobular inflammation were reduced (35). In contrast, the authors found vitamin E superior to placebo as a therapy for NASH in patients without diabetes (35). These data support the beneficial effect of pioglitazone in NAFLD/NASH, mainly in patients with T2DM, most likely because of the metabolic properties of PPAR- γ .

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of glucose-lowering agents, which have additional

benefits in patients with NAFLD/NASH through weight loss, increasing insulin sensitivity and even a direct effect on suppression of lipogenesis in hepatocytes (36). Liraglutide was studied in different doses starting from 0.3 mg to 3 mg/day, and it improved biological and clinical parameters i.e. AST, ALT, BMI, HbA1c, fasting plasma glucose, visceral fat accumulation, along with reducing hepatic steatosis assessed through either ultrasonography or MRI in patients with T2DM and NAFLD/NASH (37,38). Liraglutide Efficacy and Action in NASH (LEAN study), a double blind, randomized control trial evaluated the effect of liraglutide administration in patients with NASH diagnosed by liver biopsy. The study included 52 patients, 17 with T2DM and 35 without, randomly assigned to either placebo or 1.8 mg/day of liraglutide. After 48 weeks, 9 out of 23 patients who received liraglutide had a reduction in primary point (resolution of steatohepatitis without worsening fibrosis), compared with 2 out of 22 in the placebo group. Also, the placebo group had worse results concerning secondary outcomes (progression in fibrosis) as well, 8 out of 22 patients vs 2 out of 23 in the liraglutide group (37).

Dipeptidyl peptidase-4 inhibitors (DPP-4i) are another category novel agents used in T2DM, with promising effects in NAFLD/NASH. Circulating DPP-4 levels were found in patients with NASH, and they were correlated with liver fibrosis and hepatocytes apoptosis (38). Sitagliptin, the most studied DPP-4i agent, showed improvements regarding ALT, AST and hepatocyte ballooning, in one study (38). At the same time, other researchers did not find benefits in the administration of sitagliptin at patients with NAFLD/NASH (39).

Empagliflozin, a sodium-glucose cotransporter two inhibitor (SGLT2i), was studied in the Effect of Empagliflozin on Liver Fat (E-LIFT) trial, which proved that it reduces liver fat and ALT levels in patients with T2DM and NAFLD (40). This class of drug that has cardiovascular benefits (41), seem to have an advantage in NAFLD. Thus, the combination between a GLP-1 RA, and an SGLT2i might have complimentary benefits for patients with T2DM, NAFLD and/or with cardiovascular disease (35).

Treatment of hyperglycemia is important in NAFLD/NASH patients, considering diabetic individuals have worse evolution of microvascular complications like retinopathy (42) and nephropathy (43). Hence, clinicians can use any glucose-lowering agents mentioned above (SGLT-2i, GLP-1 RA, DPP-4i) to achieve T2DM control before debut of complications, and simultaneous treatment of NAFLD (34).

6. Conclusions

The research on non-invasive diagnostic tools, effective and safe therapies in NAFLD is interposed with other highly prevalent diseases like T2DM. These two pathologies are interrelated having common risk factors, similar prognosis and significant socioeconomic burden. Thus, an active screening for NAFLD/NASH in patients with diabetes and vice-versa is useful for the prevention of the aggravation of both diseases.

Clinicians should put more emphasis on lifestyle interventions, through empowering patients in taking responsibility and being aware of their essential role in managing NAFLD/NASH.

Although there is no specific treatment for NAFLD/NASH, agents with pleiotropic effects that target multiple pathogenic

mechanisms such as thiazolidinediones, GLP-1 RA, SGLT2i or vitamin E proved to be beneficial in some studies. Whether these treatments slow the rate of NAFLD/NASH progression to fibrosis and cirrhosis will be decided by future studies.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

APS, RAS and AIS conceived and designed the study. CB, CS and SDS acquired the data and performed the literature research. ES, FG, and REB verified and selected the studies for the final analysis. CS, AIS, REB and SDS have equal contributions with first author. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

APS is currently Vice President of the Romanian National Diabetes Committee and has given talks, attended conferences and participated in advisory boards sponsored by various pharmaceutical companies. RAS attended conferences sponsored by Wörwag Pharma. The rest of the authors declare that they have no competing interests.

References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, *et al*; IDF Diabetes Atlas Committee: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 157: 107843, 2019.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR and Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *BMJ* 316: 823-828, 1998.
3. Zafir B and Plutzky J: Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes. In: *International Textbook of diabetes mellitus*. DeFronzo RA, Ferrannini E, Zimmet P and Alberti KGMM (eds). John Wiley & Sons, Ltd., West Sussex, pp1031-1045, 2015.
4. Bratu O, Mischianu D and Constantinoiu S: Transobturator urethral suspension surgical treatment of urinary incontinence in men. *Chirurgia (Bucur)* 108: 250-255, 2013.

5. Hsia DS and Cefalu WT: The relationship between obesity and type 2 diabetes - the role of gut factors. In: International Textbook of Diabetes Mellitus. DeFronzo RA, Ferrannini E, Zimmet P and Alberti KGMM (eds). John Wiley & Sons, Ltd., West Sussex, pp469-478, 2015.
6. World Health Organization: Obesity and overweight. <https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed March 31, 2020.
7. Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I and Nader F: Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. *Diabetes Care* 43: 283-289, 2020.
8. Vernon G, Baranova A and Younossi ZM: Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 34: 274-285, 2011.
9. Marchesini G and Mazzotti A: NAFLD incidence and remission: Only a matter of weight gain and weight loss? *J Hepatol* 62: 15-17, 2015.
10. Estes C, Razavi H, Loomba R, Younossi Z and Sanyal AJ: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology* 67: 123-133, 2018.
11. Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, Tilg H, Roden M, Gatsaldelli A, Yki-Jarvinen H, *et al*; European Association for the Study of Obesity (EASO): EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. *Obes Facts* 9: 65-90, 2016.
12. Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G and Perseghin G: NAFLD/NASH in patients with type 2 diabetes and related treatment options. *J Endocrinol Invest* 41: 509-521, 2018.
13. Tang A, Hallouch O, Chernyak V, Kamaya A and Sirlin CB: Epidemiology of hepatocellular carcinoma: Target population for surveillance and diagnosis. *Abdom Radiol (NY)* 43: 13-25, 2018.
14. Gastaldelli A and Cusi K: From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. *JHEP Rep* 1: 312-328, 2019.
15. Milić S, Lulić D and Štimac D: Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. *World J Gastroenterol* 20: 9330-9337, 2014.
16. Schuppan D, Surabattula R and Wang XY: Determinants of fibrosis progression and regression in NASH. *J Hepatol* 68: 238-250, 2018.
17. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH and Loomba R: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 13: 643-54.e1, 9, quiz e39-e40, 2015.
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 55: 2005-2023, 2012.
19. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E and Bass NM: Nonalcoholic Steatohepatitis Clinical Research Network: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 56: 943-951, 2012.
20. Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wyleźń M, Lange D and Liszka L: Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. *Hepatol Int* 7: 233-240, 2013.
21. Hazlehurst JM, Woods C, Marjot T, Cobbald JF and Tomlinson JW: Non-alcoholic fatty liver disease and diabetes. *Metabolism* 65: 1096-1108, 2016.
22. Bril F and Cusi K: Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action. *Diabetes Care* 40: 419-430, 2017.
23. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E and Clark JM: Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. *Hepatology* 54: 1082-1090, 2011.
24. Castera L, Friedrich-Rust M and Loomba R: Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. *Gastroenterology* 156: 1264-1281.e4, 2019.
25. Yki-Järvinen H: Diagnosis of non-alcoholic fatty liver disease (NAFLD). *Diabetologia* 59: 1104-1111, 2016.
26. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL and Wing RR: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 51: 121-129, 2010.
27. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M and Romero-Gomez M: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology* 149: 367-78.e5, quiz e14-e15, 2015.
28. Mummadi RR, Kasturi KS, Chennareddygar S and Sood GK: Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 6: 1396-1402, 2008.
29. Della Pepa G, Vetrani C, Lombardi G, Bozzetto L, Annuzzi G and Rivellesse AA: Isocaloric dietary changes and non-alcoholic fatty liver disease in high cardiometabolic risk individuals. *Nutrients* 9: 1065, 2017.
30. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond PV, Johnson NA and Wilson AM: The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol* 59: 138-143, 2013.
31. Eslamparast T, Tandon P and Raman M: Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. *Nutrients* 9: 800, 2017.
32. Epingeac ME, Gaman MA, Diaconu C, Gad M and Gaman AM: The evaluation of oxidative stress in obesity. *Rev Chim* 70: 2241-2244, 2019.
33. Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M and Mantzoros CS: Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; New kids on the block. *Curr Vasc Pharmacol* 18: 172-181, 2020.
34. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, *et al*: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. *Ann Intern Med* 165: 305-315, 2016.
35. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, *et al*; NASH CRN: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 362: 1675-1685, 2010.
36. Ranjbar G, Mikhailidis DP and Sahebkar A: Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! *Metabolism* 101: 154001, 2019.
37. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, *et al*; LEAN trial team: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 387: 679-690, 2016.
38. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C and Duman DG: Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. *Acta Gastroenterol Belg* 75: 240-244, 2012.
39. Asakawa M, Mitsui H, Akihisa M, Sekine T, Niitsu Y, Kobayashi A, Miyake A, Hashimoto N, Kawamura M and Ogawa Y: Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury. *Springerplus* 4: 346, 2015.
40. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, *et al*: Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial). *Diabetes Care* 41: 1801-1808, 2018.
41. Diaconu C: Treatment of diabetes in patients with heart failure. In: Proceedings of the 3rd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications - Diabetes Mellitus as Cardiovascular Disease. INTERDIAB 2017, Bucharest, pp170-177, 2017.
42. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C and Muggeo M: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. *Diabetologia* 51: 444-450, 2008.
43. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, *et al*: Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. *PLoS Med* 11: e1001680, 2014.